UK markets closed

Bayer Aktiengesellschaft (BAYZF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
59.60-1.94 (-3.15%)
At close: 11:36AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close61.54
Open59.60
Bid0.00 x 0
Ask0.00 x 0
Day's range59.60 - 59.60
52-week range46.76 - 72.18
Volume301
Avg. volume5,082
Market cap58.744B
Beta (5Y monthly)1.34
PE ratio (TTM)N/A
EPS (TTM)-11.98
Earnings dateN/A
Forward dividend & yield2.42 (4.07%)
Ex-dividend date28 Apr 2021
1y target estN/A
  • Bayer to book extra $4.5 billion provision for Roundup litigation
    Reuters

    Bayer to book extra $4.5 billion provision for Roundup litigation

    FRANKFURT (Reuters) -Bayer said on Thursday it would book an additional provision of $4.5 billion related to litigation which alleges that its weedkiller Roundup can cause cancer. Bayer made the announcement in an update to investors on how it plans to deal with Roundup-related lawsuits that have dogged the company since it acquired the brand as part of its $63 billion purchase of Monsanto in 2018. The decision comes after a U.S. judge in May rejected Bayer's plan to try to limit the cost of future class action over claims that Roundup causes cancer.

  • Bayer says to appeal U.S. court ruling on PCBs if necessary
    Reuters

    Bayer says to appeal U.S. court ruling on PCBs if necessary

    German chemicals maker Bayer said on Wednesday it may appeal an order in a U.S. legal case to pay $185 million to four staff members of a school in the state of Washington over exposure to polychlorinated biphenyls, or PCBs, made by the former Monsanto Co. Bayer, which bought Monsanto for $63 billion in 2018, said it disagreed with the verdict and planned to pursue post-trial motions and, if necessary, an appeal. "The undisputed evidence in this case does not support the conclusions that plaintiffs were exposed to unsafe levels of PCBs at the Sky Valley Education Center (SVEC) or that any exposure could have possibly caused their claimed injuries," Bayer said in a statement.